ALZN

Companies
NASDAQ
Alzamend Neuro Inc.
Health Care
Price Chart
Overview

About ALZN

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Market Cap
$4.3M
Volume
423.0K
Avg. Volume
533.6K
P/E Ratio
-0.20415384
Dividend Yield
0.00%
Employees
7.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.89
Moderate Correlation
Volatility
High (1.00)
Relative to market
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for ALZN.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, ALZN shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$4.3M
Volume423.0K
P/E Ratio-0.20
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
September 12, 2024

PortfolioPilot Analysis

Get AI-powered insights on how ALZN fits into your investment strategy and portfolio diversification.

Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025